Drugs that contain Glecaprevir; Pibrentasvir
1. Drug name - MAVYRET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(9 years from now) | |
| US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(9 years from now) | |
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(12 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(12 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209703A | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN104829688A | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN104829688B | ABBVIE INC | Macrocyclic Proline-Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN103209703B | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2618831B1 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2618831A1 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2618831A4 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(8 years from now) | |
|
US10028937
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(8 years from now) | |
|
US10039754
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(8 years from now) | |
|
US9586978
(Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(8 years from now) | |
|
US8648037
(Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(9 years from now) | |
|
US8937150
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(10 years from now) | |
| US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(11 years from now) | |
|
US10286029
(Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(11 years from now) | |
|
USRE48923
(Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(13 years from now) | |
|
US9321807
(Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(13 years from now) | |
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
|
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(14 years from now) | |
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: PELLETS;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG;20MG/PACKET | PELLETS;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.